CollPlant Biotechnologies reported GAAP revenues of $179,000 for the second quarter ended June 30, 2025, a decrease from $249,000 in Q2 2024, mainly due to reduced sales of rhCollagen-based products. However, GAAP revenues for the six months ended June 30, 2025, increased to $2.2 million from $347,000 in the prior year, primarily driven by a $2 million AbbVie milestone payment in February 2025.
The company's GAAP net loss for the second quarter was $3.3 million, or $0.28 basic loss per share, an improvement from a net loss of $4.2 million, or $0.37 basic loss per share, in Q2 2024. For the six months, the GAAP net loss decreased to $4.8 million, or $0.41 basic loss per share, from $8.4 million, or $0.73 basic loss per share, in the corresponding period of 2024.
As of June 30, 2025, cash and cash equivalents stood at $11.4 million. Cash provided by financing activities for the six months was $3.1 million, attributed to a registered direct offering in June 2025. CollPlant also provided updates on its photocurable dermal filler program, which is in the final stages of preclinical testing, and continued progress in its regenerative breast implant program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.